SOURCE: Wall Street Equity Research

Wall Street Equity Research

January 18, 2011 08:23 ET

Professional Research on Teva Pharmaceutical Industries Limited and Endo Pharmaceuticals Holdings Inc. -- Drug Manufacturers Expanding Reach, Coping With FDA

JOHANNESBURG, SOUTH AFRICA--(Marketwire - January 18, 2011) - allows shareholders to gain full understanding of the economic and market forces influencing the drug manufacturers - other industry, and offers free research on industry players Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) and Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP). Register today at to receive free research reports on these companies.

While the expiration of drug patents has been a burden to some major companies in the Drug Manufacturers industry lately, companies in the Drug Manufacturers - Other sector, which have interests in brand name as well as generic markets, are faring better. Visit us at to understand the catalysts and forces driving or affecting drug manufacturers - other stocks. is a specialized website where investors can have complete access to free reports on drug manufacturers - other industry; traders looking for analyst opinions on Teva Pharmaceutical Industries Limited, Endo Pharmaceuticals Holdings Inc. and other players in the industry are welcomed to sign up for a free one year membership at

Companies in this sector have recently been looking to acquire products and businesses that address their expansion needs. Some like Teva Pharmaceutical Industries Limited have bought smaller companies in the women's health arena, while others are focusing their efforts on cancer. Shareholders and investors can sign up today at to download the full report on Teva Pharmaceutical Industries Limited.

Though some in the industry have been posting positive financials, the constant make or break for the industry is FDA approval. A few companies such as Endo Pharmaceuticals Holdings Inc. have recently been denied approval for some of their products, and have been asked to provide more information before being approved. The FDA's recent announcement that they are trying to decrease the allowable amount of acetaminophen in prescription medicines may also prove a detriment to some. The proposed decrease comes amid concerns that high levels of acetaminophen can damage the liver. Shareholders and investors can sign up today at to download the full report on Endo Pharmaceuticals Holdings Inc.

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

Contact Information